$RVTY

T. Rowe Price (RVTY) reports 16.4% Revvity stake, 18.3M shares under control

T. Rowe Price Investment Management, an institutional investment adviser, disclosed beneficial ownership of 18,269,089 shares of Revvity Inc common stock, or 16.4% of the class. It reported sole voting power over 17,089,376 shares and sole dispositive power over 18,269,089 shares. The T. Rowe Price Capital Appreciation Fund holds 11,237,061 shares (10.1%).

Original reporting
Published Aug 14, 2026, 2:42 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 15, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$RVTY
Neutral
medium confidence
Mentioned
$RVTY
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$RVTYNeutralLow
01

Why it matters

A 16.4% stake is material in size, but the text provides no new operational, regulatory, or strategic actions by Revvity.

02

Market read

Traders may use the disclosure to reassess ownership concentration and potential future catalysts, but the article itself contains no new Revvity fundamentals.

03

What to watch

The article does not specify whether the stake is newly initiated, whether there are plans to engage management, or whether the position is part of a broader strategy.

Relevance 4/10Novelty 4/10Timing: as-of the latest ownership filing date, for positioning review

Background

The article summarizes a beneficial ownership disclosure by T. Rowe Price Investment Management regarding Revvity common stock.

Company-level read

Ticker impact

$RVTYNeutralMedium confidence
Context

T. Rowe Price Investment Management discloses beneficial ownership of 18,269,089 Revvity shares, 16.4% of the class.

Expected impact

Likely limited immediate price impact; any effect would be through positioning/attention rather than new operating information.

Evidence & confidence

This is a beneficial ownership disclosure (13D/13G-style information) with no accompanying deal, guidance, or operational change described in the text.

Market effects

Could modestly increase attention on Revvity among institutional investors, but no sector-wide signal is provided.

None indicated.

None indicated.

Counterpoint

A large stake disclosure may reflect passive or client-driven holdings rather than an activist intent, limiting follow-through impact on the stock.

Key entities

  • RVTY

    Revvity Inc., the issuer whose shares are subject of the beneficial ownership disclosure.

  • T. Rowe Price Investment Management, Inc.

    Disclosing entity reporting beneficial ownership and voting/dispositive power details.

Related articles

$RVTYHighAI 9/10

Revvity (RVTY) Q2 2026 Earnings Call Transcript

Revvity (RVTY) reported Q2 2026 pro forma revenue of $711 million, up 3% organically, and pro forma adjusted EPS of $1.41. Diagnostics revenue rose 11% organically, while Signals software declined 20% organically. Free cash flow was $184 million. Full-year organic growth guidance was raised to 4% to 5% and adjusted EPS to $5.30 to $5.40.

$RVTYMedAI 8/10

Revvity Q2 Earnings Call Highlights

Revvity (RVTY) reported Q2 results on an earnings call, with Diagnostics revenue of $352M up 12% reported and 11% organic. Life Sciences revenue was $359M, down 2% reported and 3% organic, driven by a ~20% Signals software decline. For 2026, it raised pro forma organic growth to 4%-5% and guided revenue $2.83B-$2.86B, adjusted EPS $5.30-$5.40. It expects Q3 revenue $685M-$700M and organic growth 4%-6%.

$RVTYMed

Revvity, Inc. Q2 2026 Earnings Call Summary

Revvity, Inc. reported Q2 2026 results, citing improving pharma and biotech spending and higher orders tied to AI-driven drug discovery. Management said Opera Phenix OptIQ demand outpaces capacity, raised full-year organic growth guidance to 4% to 5%, and expects Signals software double-digit growth in H2. It signed an agreement to divest China immunodiagnostics and targets gross leverage below 3x by year-end.

$RVTYMedAI 8/10

Why Revvity (RVTY) Stock Is Up Today

Revvity (NYSE: RVTY) shares rose about 3% after the company reported Q2 2026 adjusted EPS of $1.41 versus $1.21 expected, and revenue of $729.68 million versus $703.39 million. Revvity lifted full-year guidance to 4% to 5% organic growth and EPS of $5.30 to $5.40. Stifel raised its target to $110 and Bernstein to $120.

$RVTYMedAI 9/10

RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up

Revvity (RVTY) reported Q2 2026 adjusted EPS of $1.41, up 19.5% and above the $1.23 Zacks estimate. Revenue rose 1.3% to $729.7 million, beating $704.5 million. Pro forma revenues were $711.1 million. Diagnostics grew; Life Sciences declined. Revvity raised 2026 pro forma revenue to $2.83-$2.86B and EPS to $5.30-$5.40 and agreed to divest China Immunodiagnostics.